Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

555.80 +8.65 (+1.58%)
Streaming Delayed Price Updated: 12:14 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
From United Therapeutics Corporation
Via Business Wire
News headline image
First Human With Pig Heart Transplant Dies: Reuters ↗
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading. 
Via Benzinga
News headline image
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world 
Via Newswire.com
News headline image
United Therapeutics Earnings Perspective: Return On Capital Employed ↗
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%... 
Via Benzinga
News headline image
FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus ↗
United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional... 
Via Benzinga
News headline image
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics's Earnings Outlook ↗
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
News headline image
First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch ↗
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
News headline image
7 Pharmaceutical Stocks That Could Make You Rich ↗
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
News headline image
Mark To Market ↗
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did. 
Via Talk Markets
News headline image
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
From United Therapeutics Corporation
Via Business Wire
News headline image
Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH ↗
The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial... 
Via Benzinga
News headline image
United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript ↗
UTHR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
News headline image
Recap: United Therapeutics Q3 Earnings ↗
United Therapeutics (NASDAQ:UTHR) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
Why Shares of MannKind Corporation Are Falling This Morning ↗
Investors are hyperventilating after a delay for its inhaled medicine. 
Via The Motley Fool
News headline image
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease ↗
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary... 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2021 ↗
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer? ↗
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
News headline image
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients ↗
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary... 
Via Benzinga
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
Via FinancialNewsMedia
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.